NTRK1 and glioblastoma: Although glioblastoma methylation subclasses are not used clinically, a recent study reported that a survival benefit was seen in glioblastomas with maximised extent of resection in receptor tyrosine kinase (RTK) 1 and RTK2 methylation subclasses, but not in the mesenchymal subclass [57].